Biogen's Early-Stage Alzheimer's Data Continues to Impress Post author:Sam Post published:November 1, 2017 Post category:BioPharma ALZ’s researchers continue to see hope in Biogen’s aducanumab. Source: BioSpace You Might Also Like <b>Seventure Partners</b> Health For Life Capital Participates In $13.2 Million Financing Of Japanese Microbiome Leader <b>Anaeropharma Science</b> July 4, 2017 FDA Gives Go-Ahead for Tetra's Phase II Trial March 15, 2018 Cancer Biotech Novocure Scores New $150M Debt Financing February 7, 2018
<b>Seventure Partners</b> Health For Life Capital Participates In $13.2 Million Financing Of Japanese Microbiome Leader <b>Anaeropharma Science</b> July 4, 2017
